Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.50 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.50 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.50 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.50 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809094 | 0.94 | ALDH1A1 (0.59) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL7590401 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28493 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL17310933 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL2954516 | 0.80 | ALDH1A1 (0.79) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28416912 | 0.79 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28557531 | 0.79 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28740008 | 0.79 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL1402759 | 0.73 | ALDH1A1 (0.79) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL9488488 | 0.73 | ALDH1A1 (0.79) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0286929-A2 | Pyrrolidine derivatives, process for their preparation, agents containing them as well as their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-10-19 | — | — | EP | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1392683-B1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE AS ANTICANCER AGENTS | CYTOVIA INC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-7053117-B2 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1392683-A4 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-1392683-A1 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002092594-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| US-4992347-A | Marking | COURTAULDS PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| EP-0301057-A1 | Forming a permanent image in a layer | COURTAULDS PLC (GB) | 1989-02-01 | — | — | EP | disclosed |
| EP-0301428-A2 | Benzyldiaminopyrimidine derivatives and their use as medicaments | EGIS GYOGYSZERGYAR (HU) | 1989-02-01 | — | — | EP | disclosed |
| WO-1988006306-A1 | MARKING | COURTAULDS PLC (GB) | 1988-08-25 | — | — | WO | disclosed |
| EP-0279600-A1 | Marking | COURTAULDS PLC (GB) | 1988-08-24 | — | — | EP | disclosed |
| US-4182629-A | Photochromic compounds | HELLER HAROLD G (GB) | 1980-01-08 | — | — | US | disclosed |
| US-4145536-A | Photochromic compounds | HELLER HAROLD G | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH1A1 412/4885CYP1A1 1306/4885CYP1B1 862/4885 |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP4, CASP3, CASP7 | ALDH1A1 2014/4885CYP1A1 111/4885CYP1B1 124/4885 |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP5, CASP1 | ALDH1A1 774/4885CYP1A1 48/4885CYP1B1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.